[
  {
    "ts": null,
    "headline": "Kite Presents New Data Underscoring Curative Potential of Yescarta速 in Relapsed/Refractory Large B-cell Lymphoma at ASH",
    "summary": "SANTA MONICA, Calif., December 08, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced findings from three new analyses for Yescarta速 (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), which were presented at 66th American Society of Hematology (ASH) Annual Meeting & Exposition.",
    "url": "https://finnhub.io/api/news?id=7dc5584b0bbb743f730cbacea5a777e3407cfc8e7ce84106b895c755f385aeec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733679000,
      "headline": "Kite Presents New Data Underscoring Curative Potential of Yescarta速 in Relapsed/Refractory Large B-cell Lymphoma at ASH",
      "id": 131865363,
      "image": "https://s.yimg.com/ny/api/res/1.2/j7ZIJS2dW2Bli17d63rPJA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0zNjE-/https://media.zenfs.com/en/business-wire.com/7b549b590d72563b418e104a82291999",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "SANTA MONICA, Calif., December 08, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced findings from three new analyses for Yescarta速 (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), which were presented at 66th American Society of Hematology (ASH) Annual Meeting & Exposition.",
      "url": "https://finnhub.io/api/news?id=7dc5584b0bbb743f730cbacea5a777e3407cfc8e7ce84106b895c755f385aeec"
    }
  }
]